Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
← catalyst calendarNCT05281471 · readout ≤ 133 d
Sponsored by Genelux Corporation (industry) · GNLX — their whole pipeline →. With GOG Foundation.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
186estimated
Sites
32
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-31 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-03-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Platinum-resistant Ovarian Cancer
- Platinum-refractory Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- High-grade Serous Ovarian Cancer
- Endometrioid Ovarian Cancer
- Ovarian Clear Cell Carcinoma
Interventions
- Biological: olvimulogene nanivacirepvec — also filed as GL-ONC1 and GLV-1h68
- Drug: Platinum chemotherapy: carboplatin (preferred) or cisplatin
- Drug: Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- Drug: Bevacizumab (or biosimilar)
Primary outcome
what the primary-completion date above is the date OFProgression-free survival (PFS) by RECIST 1.1 in the Intention-to-Treat (ITT) population (all randomized participants regardless of whether they received any dose of treatment)
measured From date of randomization up to 12 months
Publications
- PMID 34686353 — reports results
- PMID 37227734 — reports results
- PMID 31567308 — cited as background
- PMID 37666539 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · GNLX's whole pipeline · Catalyst calendar · Every registered study · What changed